-
The Clinical Outcome and Risk Factors Analysis of Immune Checkpoint Inhibitor-Based Treatment in Lung Adenocarcinoma Patients With Brain Metastases
A new study examines the real-world evidence for the efficacy and clinical outcomes of immune checkpoint inhibitor-based therapy in lung cancer patients with brain metastases.
September 01, 2022
-
The Efficacy and Safety of Albumin-Bound Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for Potentially Resectable Lung Squamous Cell Carcinoma
Is this regimen a safe and effective option for the neoadjuvant treatment of potentially resectable lung squamous cell carcinoma?
August 01, 2022
-
The Oncogenic Landscape of the Idiopathic Pulmonary Fibrosis: A Narrative Review
Recent advances have helped further our understanding of the link between idiopathic pulmonary fibrosis and lung cancer, contributing to improvements in diagnosis and treatment.
July 01, 2022
-
Rate and Risk Factors of Recurrent Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
Pneumonitis is a known complication associated with immune checkpoint inhibitor treatment. How often do recurrent episodes occur in lung cancer patients, and what are the risk factors?
June 02, 2022
-
Neoadjuvant Immunotherapy or Chemoimmunotherapy in Non-Small Cell Lung Cancer
How do these treatments for non-small cell lung cancer compare? Is one more beneficial than the other?
May 02, 2022
-
Safety and Efficacy of Nivolumab Plus Recombinant Human Endostatin in Previously Treated Advanced Non-Small-Cell Lung Cancer
This combination therapy shows promise as a potential safe and effective option for advanced NSCLC patients who did not adequately respond to previous treatment.
April 01, 2022
-
Pembrolizumab Monotherapy or Combination Therapy for Bone Metastases in Advanced Non-Small Cell Lung Cancer
Pembrolizumab therapy, either alone or in combination, may be an effective treatment option for bone metastases in non-small cell lung cancer patients.
March 14, 2022
-
Prognostic Significance of Procalcitonin in Small Cell Lung Cancer
What could procalcitonin levels tell us about the prognosis of small cell lung cancer patients?
February 28, 2022
-
Real-World Experience of Afatinib as First-Line Therapy for Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Korea
Real-world data supports the safety and efficacy of afatinib in patients with EGFR mutation-positive NSCLC.
February 11, 2022
-
Use of Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer in Real-life Practice
Do the benefits of adjuvant chemotherapy in resected NSCLC seen in clinical trials translate to real-life practice?
January 28, 2022
-
Clinical Features and Prognostic Factors of Combined Small Cell Lung Cancer
What could this newly developed nomogram tell us about the prognosis of combined small-cell lung cancer patients?
January 20, 2022
-
Expert Consensus on Resection of Chest Wall Tumors and Chest Wall Reconstruction
An expert consensus provides recommendations for chest wall tumor resection and reconstruction.
January 06, 2022
-
The Safety and Efficacy of Immunotherapy With Anti-Programmed Cell Death 1 Monoclonal Antibody for Lung Cancer Complicated With Mycobacterium Tuberculosis Infection
Is this treatment a safe and effective option for lung cancer patients with tuberculosis infection?
December 10, 2021
-
Are There Differences By Sex in Lung Cancer Characteristics At Diagnosis?
A new study examines the question of whether lung cancer characteristics at diagnosis differ between men and women. What have we learned?
November 26, 2021
-
Prognostic and Predictive Impact of Creatine Kinase Level in Non-Small Cell Lung Cancer Treated With Tyrosine Kinase Inhibitors
What could creatine kinase levels tell us about TKI treatment response and the prognosis of NSCLC patients?
November 12, 2021
-
Expert Consensus on Perioperative Immunotherapy for Local Advanced Non-Small Cell Lung Cancer
This paper summarizes the discussions and expert consensus recommendations regarding the use of immunotherapy for NSCLC in the perioperative setting.
October 29, 2021
-
Surgical Mediastinal Lymph Node Staging for Non-Small-Cell Lung Carcinoma
A new study compares two techniques for the mediastinal staging of non-small-cell lung cancer. Is one superior to the other?
October 18, 2021
-
Outcomes of Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) That Harbor a STK11 Mutation
A better understanding of the impact of STK11 mutations on stage III NSCLC outcomes could have important prognostic and therapeutic implications.
October 04, 2021
-
Diagnostic and Prognostic Biomarkers in Oligometastatic Non-Small Cell Lung Cancer
Novel blood- and tissue-based biomarkers could serve as reliable tools in the management of oligometastatic non-small cell lung cancer.
September 13, 2021
-
Consistency of Recommendations for the Diagnosis and Treatment of Non-Small Cell Lung Cancer
A new review finds variations in diagnosis and treatment recommendations for non-small cell lung cancer, highlighting the need for more consistent guidelines.
September 06, 2021
